Cargando…
Engineered soluble ACE2 receptor: Responding to change with change
SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891289/ https://www.ncbi.nlm.nih.gov/pubmed/36741399 http://dx.doi.org/10.3389/fimmu.2022.1084331 |
_version_ | 1784881110691348480 |
---|---|
author | Li, Guangyao Qian, Kewen Zhang, Shuyi Fu, Wenyan Zhao, Jian Lei, Changhai Hu, Shi |
author_facet | Li, Guangyao Qian, Kewen Zhang, Shuyi Fu, Wenyan Zhao, Jian Lei, Changhai Hu, Shi |
author_sort | Li, Guangyao |
collection | PubMed |
description | SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that occurred early in the pandemic is gradually showing signs of slowing. While recombinant soluble ACE2, as an alternative therapy, has been modified by many engineering methods, both the safety and functional aspects are approaching maturity, and this therapy shows great potential for broadly neutralizing coronaviruses, but its progress in clinical development remains stalled. Therefore, there are still several key problems to be considered and solved for recombinant soluble ACE2 to be approved as a clinical treatment as soon as possible. |
format | Online Article Text |
id | pubmed-9891289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98912892023-02-02 Engineered soluble ACE2 receptor: Responding to change with change Li, Guangyao Qian, Kewen Zhang, Shuyi Fu, Wenyan Zhao, Jian Lei, Changhai Hu, Shi Front Immunol Immunology SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that occurred early in the pandemic is gradually showing signs of slowing. While recombinant soluble ACE2, as an alternative therapy, has been modified by many engineering methods, both the safety and functional aspects are approaching maturity, and this therapy shows great potential for broadly neutralizing coronaviruses, but its progress in clinical development remains stalled. Therefore, there are still several key problems to be considered and solved for recombinant soluble ACE2 to be approved as a clinical treatment as soon as possible. Frontiers Media S.A. 2023-01-18 /pmc/articles/PMC9891289/ /pubmed/36741399 http://dx.doi.org/10.3389/fimmu.2022.1084331 Text en Copyright © 2023 Li, Qian, Zhang, Fu, Zhao, Lei and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Guangyao Qian, Kewen Zhang, Shuyi Fu, Wenyan Zhao, Jian Lei, Changhai Hu, Shi Engineered soluble ACE2 receptor: Responding to change with change |
title | Engineered soluble ACE2 receptor: Responding to change with change |
title_full | Engineered soluble ACE2 receptor: Responding to change with change |
title_fullStr | Engineered soluble ACE2 receptor: Responding to change with change |
title_full_unstemmed | Engineered soluble ACE2 receptor: Responding to change with change |
title_short | Engineered soluble ACE2 receptor: Responding to change with change |
title_sort | engineered soluble ace2 receptor: responding to change with change |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891289/ https://www.ncbi.nlm.nih.gov/pubmed/36741399 http://dx.doi.org/10.3389/fimmu.2022.1084331 |
work_keys_str_mv | AT liguangyao engineeredsolubleace2receptorrespondingtochangewithchange AT qiankewen engineeredsolubleace2receptorrespondingtochangewithchange AT zhangshuyi engineeredsolubleace2receptorrespondingtochangewithchange AT fuwenyan engineeredsolubleace2receptorrespondingtochangewithchange AT zhaojian engineeredsolubleace2receptorrespondingtochangewithchange AT leichanghai engineeredsolubleace2receptorrespondingtochangewithchange AT hushi engineeredsolubleace2receptorrespondingtochangewithchange |